Immunome Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-106.81	-37.52	-24.71	-17.84	-10.44	-7.85
Depreciation & Amortization	0.73	0.63	0.76	0.76	0.62	0.52
Share-Based Compensation	6.22	5.33	3.45	0.62	0.01	0.01
Other Operating Activities	92.29	2.24	2.28	4.33	0.22	-0.09
Operating Cash Flow	-7.57	-28.69	-18.23	-12.13	-9.6	-7.41
Capital Expenditures	-0.83	-0.25	-0.08	-0.59	-0.23	-0.23
Acquisitions	9.28	0	0	0	0	0
Change in Investments	-38.93	0	0	0	0	0
Investing Cash Flow	-30.48	-0.25	-0.08	-0.59	-0.23	-0.23
Share Issuance / Repurchase	125.41	0.03	28.66	44.87	0.01	0
Debt Issued / Paid	0	0	-0.11	0.05	6.19	-0.55
Other Financing Activities	-9	-	-0.78	5.02	4.58	-
Financing Cash Flow	116.41	0.03	27.77	49.94	10.77	-0.55
Net Cash Flow	78.36	-28.91	9.46	37.22	0.94	-8.19
Free Cash Flow	-8.4	-28.94	-18.31	-12.72	-9.83	-7.63
Free Cash Flow Margin	-59.92%	-	-	-	-	-
Free Cash Flow Per Share	-0.42	-2.39	-1.59	-3.75	-8.99	-1.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).